Nosantine

Notice: hodoodo.ccom website will be shut down by June 30, 2025. Its business will be taken care by MedKoo Bioscience. Please visit medkoo.com for your research need.

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H584863

CAS#: 76600-30-1

Description: Nosantine is an immunomodulating compound related to inosine in structure and isoprinosine in action that enhances T-cell dependent immune responses.

Chemical Structure

img
Nosantine
CAS# 76600-30-1
Instruction

Theoretical Analysis

Hodoodo Cat#: H584863
Name: Nosantine
CAS#: 76600-30-1
Chemical Formula: C14H22N4O2
Exact Mass: 278.17
Molecular Weight: 278.356
Elemental Analysis: C, 60.41; H, 7.97; N, 20.13; O, 11.50

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Nosantine; NPT 15392

IUPAC/Chemical Name: 6H-Purin-6-one, 1,9-dihydro-9-(1-(1-hydroxyethyl)heptyl)-, (R*,S*)-

InChi Key: RSMDQPNZAPMDJC-MNOVXSKESA-N

InChi Code: InChI=1S/C14H22N4O2/c1-3-4-5-6-7-11(10(2)19)18-9-17-12-13(18)15-8-16-14(12)20/h8-11,19H,3-7H2,1-2H3,(H,15,16,20)/t10-,11+/m1/s1

SMILES Code: O=C1NC=NC2=C1N=CN2[C@H]([C@H](O)C)CCCCCC

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 278.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Coffey RG, Hartley L, Polson JB, Krzanowski JJ, Hadden JW. Selective inhibition by NPT 15392 of lymphocyte cyclic GMP phosphodiesterase. Biochem Pharmacol. 1984 Nov 1;33(21):3411-7. PubMed PMID: 6093811.

2: Exon JH, Henningsen GM, Koller LD, Talcott PA. The selectivity of isoprinosine, NPT 15392, avridine and cyclophosphamide on multiple immune responses in rats. Int J Immunopharmacol. 1986;8(1):53-62. PubMed PMID: 2420733.

3: Hadden JW, Hadden EM, Spira T, Settineri R, Simon L, Giner-Sorolla A. Effects of NPT 15392 in vitro on human leukocyte functions. Int J Immunopharmacol. 1982;4(3):235-42. PubMed PMID: 6179891.

4: Donnelly RP, Tsang KY, Bishop LR, Fudenberg HH. Kinetic analysis of the immunopotentiating effect of the hypoxanthine analogue, NPT-15392, on the interleukin-2 production potential of human lymphocytes. Int J Immunopharmacol. 1986;8(6):621-7. PubMed PMID: 3491799.

5: Jones C, Lee C, Hoehler F, Koyama P, Skinner W, Lamott JA. Observations on the immunomodulator NPT 15392 in New Zealand Black mice. Int J Immunopharmacol. 1983;5(1):85-90. PubMed PMID: 6840935.

6: Florentin I, Taylor E, Davigny M, Mathé G, Hadden JW. Kinetic studies of the immunopharmacologic effects of NPT 15392 in mice. Int J Immunopharmacol. 1982;4(3):225-33. PubMed PMID: 6213574.

7: Wiranowska-Stewart M, Hadden JW. Effects of isoprinosine and NPT 15392 on interleukin-2 (IL-2) production. Int J Immunopharmacol. 1986;8(1):63-9. PubMed PMID: 2420734.

8: Simon LN, Hoehler FK, McKenzie DT, Hadden JW. Isoprinosine and NPT 15392: immunomodulation and cancer. Adv Exp Med Biol. 1983;166:241-59. PubMed PMID: 6196956.

9: Ikehara S, Hadden JW, Good RA, Lunzer DG, Pahwa RN. In vitro effects of two immunopotentiators, Isoprinosine and NPT 15392, on murine T-cell differentiation and function. Thymus. 1981 Aug;3(2):87-95. PubMed PMID: 6170135.

10: Merluzzi VJ, Walker MM, Williams N, Susskind B, Hadden JW, Faanes RB. Immunoenhancing activity of NPT 15392: a potential immune response modifier. Int J Immunopharmacol. 1982;4(3):219-24. PubMed PMID: 7049973.

11: De Simone C, Cilli A, Zanzoglu S, Pugnaloni L, De Santis S, Sorice F. The effect of NPT 15392, 9-(erythro-2-hydroxy-3-nonyl)-6-hydroxypurine, on the phytohemagglutinin of OKT3+, OKT4+, OKT8+, and OKM1+ cell-depleted and undepleted peripheral blood mononuclear cells. Clin Immunol Immunopathol. 1984 Nov;33(2):191-8. PubMed PMID: 6488589.

12: Favre R, Bagarry-Liegey D, Jeanroy B, Pignon T, Meyer G, Carcassonne Y. Immunomodulation by NPT 15392 in cancer patients under chemotherapy. Adv Exp Med Biol. 1983;166:261-8. PubMed PMID: 6650281.

13: O'Neill BB, Ginsberg T, Hadden J. Immunopharmacology of the hypoxanthine containing compounds isoprinosine and NPT 15392. Prog Clin Biol Res. 1984;161:525-41. Review. PubMed PMID: 6207547.

14: Fudenberg HH, Whitten HD. Immunostimulation: synthetic and biological modulators of immunity. Annu Rev Pharmacol Toxicol. 1984;24:147-74. Review. PubMed PMID: 6203479.

15: Hadden JW, Keskiner Merriam L. Immunopharmacologic bases of immunotherapy. Clin Physiol Biochem. 1985;3(2-3):111-9. Review. PubMed PMID: 2408810.

16: Eichelberg D, Schmutzler W. [Pharmacological aspects of immunostimulants]. Immun Infekt. 1983 Jun;11(4):109-22. Review. German. PubMed PMID: 6085319.

17: Berendt MJ, Ives JL. Developmental status of synthetic immunomodulators. Year Immunol. 1985:193-201. Review. PubMed PMID: 2437723.

18: Wybran J. The immunopharmacology of synthetic immunomodulators. Prog Clin Biol Res. 1983;132E:95-103. PubMed PMID: 6196792.

19: Pfadenhauer EH, Bankert CS, Jensen J, Jones CE, Jenkins EE, McCloskey JA. Identification of the metabolites of erythro-9-(2-hydroxy-3-nonyl)hypoxanthine from laboratory animals. Drug Metab Dispos. 1984 May-Jun;12(3):280-4. PubMed PMID: 6145553.

20: Hadden JW. Chemically defined immunotherapeutic agents. Prog Clin Biol Res. 1983;132E:273-86. PubMed PMID: 6196787.